Abstract
Background: The role of hormonal replacement therapy in menopause is under debate. The premature closure of the Women’s Health Initiative (WHI) study in 2002 is still a source of concern among treating physicians. Objectives: The interest in alternatives to conventional hormone therapy has significantly increased. The adoption of personalized steroid hormone galenic preparations, formulated by compounding pharmacies, has recently spread. Methods: In June 2023, an extensive literature search was conducted by different authors to identify relevant studies in various databases (MEDLINE, Embase, PubMed, and Cochrane). The studies that met the inclusion and exclusion criteria were further analyzed, and relevant data were extracted and analyzed for each paper. Any discrepancies between the investigators were resolved through a consensus approach. Outcomes: The primary outcomes observed included the clinical utility of CBHT. This study reviewed the current evidence on the utility of compounded bioidentical hormones, concluding that improving knowledge and awareness of bioidentical hormones is necessary to consider their use in clinical practice. Conclusion and Outlook: These formulations might provide effective options to best tailor therapies to each patient.
Journal Section:
Narrative Review
References
1.
Davis
SR
, Lambrinoudaki
I
, Lumsden
M
, Mishra
GD
, Pal
L
, Rees
M
, et al. Menopause
. Nat Rev Dis Primers
. 2015
;1
:15004
.2.
Sarri
G
, Davies
M
, Lumsden
MA
; Guideline Development Group
. Diagnosis and management of menopause: summary of NICE guidance
. BMJ
. 2015
;351
:h5746
.3.
El Khoudary
SR
, Aggarwal
B
, Beckie
TM
, Hodis
HN
, Johnson
AE
, Langer
RD
, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American heart association
. Circulation
. 2020
;142
(25
):e506
–32
.4.
Nappi
RE
, Simoncini
T
. Menopause transition: a golden age to prevent cardiovascular disease
. Lancet Diabetes Endocrinol
. 2021
;9
(3
):135
–7
.5.
Biglia
N
, Cagnacci
A
, Gambacciani
M
, Lello
S
, Maffei
S
, Nappi
RE
. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases
. Climacteric
. 2017
;20
(4
):306
–12
.6.
Harlow
SD
, Gass
M
, Hall
JE
, Lobo
R
, Maki
P
, Rebar
RW
, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging
. Menopause
. 2012
;19
(4
):387
–95
.7.
Silva
TR
, Oppermann
K
, Reis
FM
, Spritzer
PM
. Nutrition in menopausal women: a narrative review
. Nutrients
. 2021
;13
(7
):2149
.8.
Santoro
N
, Braunstein
GD
, Butts
CL
, Martin
KA
, McDermott
M
, Pinkerton
JV
. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement
. J Clin Endocrinol Metab
. 2016
;101
(4
):1318
–43
.9.
Endocrine Society
. Bioidentical hormones: position statement
. 2006
. Available from: http://www.endo-society.org/advocacy/policy/upload/BH_position_Statement_final_10_25_06_w_Header.pdf [accessed April 6, 2011].12.
Stuenkel
CA
, Davis
SR
, Gompel
A
, Lumsden
MA
, Murad
MH
, Pinkerton
JV
, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline
. J Clin Endocrinol Metab
. 2015
;100
(11
):3975
–4011
.13.
Files
JA
, Ko
MG
, Pruthi
S
. Bioidentical hormone therapy
. Mayo Clin Proc
. 2011
;86
(7
):673
–80
, quiz 680.14.
Avis
NE
, Crawford
SL
, Greendale
G
, Bromberger
JT
, Everson-Rose
SA
, Gold
EB
, et al. Duration of menopausal vasomotor symptoms over the menopause transition
. JAMA Intern Med
. 2015
;175
(4
):531
–9
.15.
Shifren
JL
, Crandall
CJ
, Manson
JE
. Menopausal hormone therapy
. JAMA
. 2019
;321
(24
):2458
–9
.16.
Shifren
JL
. Genitourinary syndrome of menopause
. Clin Obstet Gynecol
. 2018
;61
(3
):508
–16
.17.
Cirigliano
M
. Bioidentical hormone therapy: a review of the evidence
. J Womens Health
. 2007
;16
(5
):600
–31
.18.
Biundo
B
, Carvalho
M
, Banov
D
, Day
AJ
. Compounded hormones for female patients: a survey assessmenof clinical practices in the US
. NAMS 2021 annual meeting poster presentation. P-6.19.
American Association of Retired Persons
. Are bioidentical hormones safe?
Available from: https://www.aarp.org/health/drugs-supplements/info-11-2010/are_bioidentical_hormones_safe.html [accessed April 15, 2022].20.
MacLennan
A
, Lester
S
, Moore
V
. Oral oestrogen replacement therapy versus placebo for hot flushes
. Cochrane Database Syst Rev
. 2001
;(1
):CD002978
.21.
Rossouw
JE
, Anderson
GL
, Prentice
RL
, LaCroix
AZ
, Kooperberg
C
, Stefanick
ML
, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial
. JAMA
. 2002
;288
(3
):321
–33
.22.
Stefanick
ML
. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration
. Am J Med
. 2005
;118
(Suppl 12B
):64
–73
.23.
Patsner
B
. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs
. Food Drug Law J
. 2008
;63
(2
):459
–91
.24.
Hersh
AL
, Stefanick
ML
, Stafford
RS
. National use of postmenopausal hormone therapy: annual trends and response to recent evidence
. JAMA
. 2004
;291
(1
):47
–53
.25.
Monti
M
, Fischetti
M
, Santangelo
G
, Galli
V
, Clemente
F
, Giannini
A
, et al. Urinary incontinence in women: state of the art and medical treatment
. Minerva Obstet Gynecol
. 2021
;73
(2
):135
–9
. Epub 2020 Aug 3.26.
Di Donato
V
, Palaia
I
, D’Aniello
D
, Musacchio
L
, Santangelo
G
, Di Mauro
F
, et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review
. Oncology
. 2020
;98
(4
):195
–201
. Epub 2020 Feb 7.27.
Hays
J
, Hunt
JR
, Hubbell
FA
, Anderson
GL
, Limacher
M
, Allen
C
, et al. The Women’s Health Initiative recruitment methods and results
. Ann Epidemiol
. 2003
;13
(9 Suppl
):S18
–77
.28.
Thompson
JJ
, Ritenbaugh
C
, Nichter
M
. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making
. BMC Womens Health
. 2017
;17
(1
):97
.29.
National Academies of Sciences
. In: Jackson
LM
, Parker
RM
, Mattison
DR
, editors. Engineering, and medicine; health and medicine division; board on health sciences policy; committee on the clinical utility of treating patients with compounded bioidentical hormone replacement therapy. The clinical utility of compounded bioidentical hormone therapy: a review of safety, effectiveness, and use
. Washington (DC)
: National Academies Press (US)
; 2020
.30.
Liu
Y
, Yuan
Y
, Day
AJ
, Zhang
W
, John
P
, Ng
DJ
, et al. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials
. Menopause
. 2022
;29
(4
):465
–82
.31.
Davis
R
, Batur
P
, Thacker
H
. Risks and effectiveness of compounded bioidentical hormone therapy: a case series
. J Womens Health
. 2014
;23
(8
):642
–8
.32.
Pinkerton
JV
, Santoro
N
. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women
. Menopause
. 2015
;22
(9
):926
–36
.33.
Sood
R
, Shuster
L
, Smith
R
, Vincent
A
, Jatoi
A
. Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians
. J Am Board Fam Med
. 2011
;24
(2
):202
–10
.34.
Dahir
M
, Travers-Gustafson
D
. Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy
. Sex Med
. 2014 Apr
;2
(1
):8
–15
.35.
Glaser
R
, York
AE
, Dimitrakakis
C
. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS)
. Maturitas
. 2011 Apr
;68
(4
):355
–61
.36.
Jankowski
MP
, Koerber
HR
. Neurotrophic Factors and Nociceptor Sensitization. In: Kruger
L
, Light
AR
, editors. Translational Pain Research: From Mouse to Man
. Boca Raton (FL
): CRC Press/Taylor & Francis
; 2010
. Chapter 2
.37.
Mahmud
K.
. Natural hormone therapy for menopause
. Gynecol Endocrinol
. 2010 Feb
;26
(2
):81
–5
.38.
Katz
S
, Morales
AJ.
Dehydroepiandrosterone (DHEA). and DHEA-sulfate (DS) as therapeutic options in menopause
. Semin Reprod Endocrinol
. 1998
;16
(2
):161
-70
.39.
Narkwichean
A
, Jayaprakasan
K
, Maalouf
WE
, Hernandez-Medrano
JH
, Pincott-Allen
C
, Campbell
BK
. Effects of dehydroepiandrosterone on in vivo ovine follicular development
. Hum Reprod
. 2014 Jan
;29
(1
):146
-54
. Epub 2013 Nov 20. Epub
2013 Nov 20
.40.
Panjari
M
, Bell
RJ
, Jane
F
, Wolfe
R
, Adams
J
, Morrow
C
, Davis
SR
. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido
. J Sex Med
. 2009 Sep
;6
(9
):2579
–90
.41.
Kalleinen
N
, Virkki
A
, Polo
O
, Himanen
SL
, Irjala
K
, Joutsen
A
, Porkka-Heiskanen
T
, Polo-Kantola
P
. The temporal relationship between growth hormone and slow wave sleep is weaker after menopause
. Sleep Med
. 2012 Jan
;13
(1
):96
-101
. Epub 2011 Dec 3. Epub
2011 Dec
3.42.
Arikawa
AY
, O'Dougherty
M
, Kaufman
BC
, Smith
AJ
, Thomas
W
, Warren
M
, Kurzer
MS
, Schmitz
KH
. Women in Steady Exercise Research (WISER): study design and methods
. Contemp Clin Trials
. 2010 Sep
;31
(5
):457
-65
. Epub 2010 May 24. Epub 2010 May 24
.43.
Witherby
S
, Johnson
J
, Demers
L
, Mount
S
, Littenberg
B
, Maclean
CD
, Wood
M
, Muss
H
. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study
. Oncologist
. 2011
;16
(4
):424
–31
.44.
Stefanick
ML
, Cochrane
BB
, Hsia
J
, Barad
DH
, Liu
JH
, Johnson
SR
. The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants
. Ann Epidemiol
. 2003
;13
(9 Suppl
):S78
–86
.45.
Santangelo
G
, Ruggiero
G
, Murina
F
, Di Donato
V
, Perniola
G
, Palaia
I
, et al. Vulvodynia: a practical guide in treatment strategies
. Int J Gynaecol Obstet
. 2023
;163
(2
):510
–20
.46.
Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee
. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy
. Obstet Gynecol
. 2012
;120
(2 Pt 1
):411
–5
.47.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
. The 2017 hormone therapy position statement of the North American Menopause Society
. Menopause
. 2017
;24
(7
):728
–53
.48.
De Villiers
TJ
, Hall
JE
, Pinkerton
JV
, Cerdas Pérez
S
, Rees
M
, Yang
C
, et al. Revised global consensus statement on menopausal hormone therapy
. Climacteric
. 2016
;19
(4
):313
–5
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
